These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 29582347)
1. In Vitro Assessment of Nasal Insufflation of Comminuted Drug Products Designed as Abuse Deterrent Using the Vertical Diffusion Cell. Boyce H; Smith D; Byrn S; Saluja B; Qu W; Gurvich VJ; Hoag SW AAPS PharmSciTech; 2018 May; 19(4):1744-1757. PubMed ID: 29582347 [TBL] [Abstract][Full Text] [Related]
2. Use of Drug Release Testing to Evaluate the Retention of Abuse-Deterrent Properties of Polyethylene Oxide Matrix Tablets. Meruva S; Rezaei L; Thool P; Donovan MD AAPS PharmSciTech; 2020 Oct; 21(7):270. PubMed ID: 33025237 [TBL] [Abstract][Full Text] [Related]
3. Preferential Oxycodone Loss of Physically Manipulated Abuse Deterrent Oxycodone HCl Extended Release Tablets Prepared for Nasal Insufflation Studies. Meng Z; Boyce HJ; Sun D; Kinjo M; Raofi S; Li T Pharm Res; 2021 Jul; 38(7):1263-1278. PubMed ID: 34128146 [TBL] [Abstract][Full Text] [Related]
4. Abuse-deterrent features of an extended-release morphine drug product developed using a novel injection-molding technology for oral drug delivery. Skak N; Elhauge T; Dayno JM; Lindhardt K J Opioid Manag; 2017; 13(6):465-472. PubMed ID: 29308592 [TBL] [Abstract][Full Text] [Related]
5. Particle size affects pharmacokinetics of milled oxycodone hydrochloride tablet products following nasal insufflation in nondependent, recreational opioid users. Raofi S; Kinjo M; Sun D; Li Z; Boyce H; Natarajan K; Frost M; Zhao L; Luke M; Lionberger R; Kelsh D; Kim MJ Clin Transl Sci; 2021 Sep; 14(5):1977-1987. PubMed ID: 33982418 [TBL] [Abstract][Full Text] [Related]
6. A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs. Cicero TJ; Ellis MS; Kasper ZA Pain; 2016 Jun; 157(6):1232-1238. PubMed ID: 27186712 [TBL] [Abstract][Full Text] [Related]
7. Assessing Drug Release from Manipulated Abuse Deterrent Formulations. Feng X; Zidan A; Kamal NS; Xu X; Sun D; Walenga R; Boyce H; Cruz CN; Ashraf M AAPS PharmSciTech; 2020 Jan; 21(2):40. PubMed ID: 31897805 [TBL] [Abstract][Full Text] [Related]
8. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users. Webster LR; Smith MD; Lawler J; Lindhardt K; Dayno JM Pain Med; 2017 Sep; 18(9):1695-1705. PubMed ID: 27651510 [TBL] [Abstract][Full Text] [Related]
9. A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation. Friedmann N; Marsman MR; de Kater AW; Burns LH; Webster LR J Opioid Manag; 2018; 14(6):437-443. PubMed ID: 30629280 [TBL] [Abstract][Full Text] [Related]
10. Application of hot-melt extrusion technology in immediate-release abuse-deterrent formulations. Wening K; Schwier S; Stahlberg HJ; Galia E J Opioid Manag; 2017; 13(6):473-484. PubMed ID: 29308593 [TBL] [Abstract][Full Text] [Related]
11. Stability of Abuse-deterrent properties of PEO-based Abuse-deterrent formulation. Kibria G; Bandaranayake B; Zheng J; Lee S; Cruz C Int J Pharm; 2023 Jan; 631():122430. PubMed ID: 36493968 [TBL] [Abstract][Full Text] [Related]
12. Crush resistance and insufflation potential of poly(ethylene oxide)-based abuse deterrent formulations. Muppalaneni S; Mastropietro DJ; Omidian H Expert Opin Drug Deliv; 2016 Oct; 13(10):1375-82. PubMed ID: 27402156 [TBL] [Abstract][Full Text] [Related]
13. Development and impact of prescription opioid abuse deterrent formulation technologies. Alexander L; Mannion RO; Weingarten B; Fanelli RJ; Stiles GL Drug Alcohol Depend; 2014 May; 138():1-6. PubMed ID: 24613631 [TBL] [Abstract][Full Text] [Related]
14. Risk based in vitro performance assessment of extended release abuse deterrent formulations. Xu X; Gupta A; Al-Ghabeish M; Calderon SN; Khan MA Int J Pharm; 2016 Mar; 500(1-2):255-67. PubMed ID: 26784976 [TBL] [Abstract][Full Text] [Related]